



Research Article

Advances in Neurology and Neuroscience

In- Silico Studies on Selected Active Constituents of *Genus* Decumbens *Species* against Allergic Bronchopulmonary Aspergillosis

A Arunprasath^{1*}, Sreeram S² and V Sankar Vel³

¹PG & Research Department of Botany, PSG College of Arts & Science, Coimbatore (TN), India

²PG & Research Department of Botany, PSG College of Arts & Science, Coimbatore (TN), India ORCID- 0000-0001-8969-0527

³PG & Research Department of Botany, PSG College of Arts & Science, Coimbatore (TN), India

*Corresponding author

A. Arunprasath Assistant Professor, PG & Research Department of Botany PSG College of Arts & Science Coimbatore- 14 Tamil Nadu- 641 014, India

Submitted: 25 Jan 2022; Accepted: 03 Feb 2022; Published: 28 Feb 2022

Citation: A Arunprasath, Sreeram S and V Sankar Vel. (2022). In-Silico Studies on Selected Active Constituents of Genus Decumbens Species against Allergic Bronchopulmonary Aspergillosis. Adv Neur Neur Sci, 5(1), 11-16

Abstract

Herbs have been employed in the treatment of various diseases and other medicinal purposes for a long time and they have been the zest of our life. Corbichonia decumbens an erect, short-lived succulent herb is found to possess zenith medicinal properties. At a first, the in-silico activity of the plant has been determined to carry out a modification in the Surfactant Protein-D (SP-D) which plays a pivotal role in defense against the Allergic Bronchopulmonary Aspergillosis (ABPA). The SP-D protein has been modified using in-silico tools thus making it more robust in containing ABPA. The protein SP-D when combined with the plant compound 1-methyl-3,5dinitro-1,2,4-triazole had binding energy of -6.98 and interactions with active site residue ASN-236, LYS-246, GLU-232, PHE-234 and, GLN-236. Being one of the first in-silico works carried out in the plant species it aims to provide a substantial base for future works and unwrap the potential of this herb in all aspects of medicinal plant science.

Keywords: ABPA, Docking Approach, Herb-Drug Interaction, Herbal Medicine, In-Silico

Introduction

The use of plants in the preparation of medicine and ethnobotanical studies is being practiced since time immemorial. The term medicinal plants have been in force since ancient times and these medicinal plants are used in the preparation of traditional medicines. In India, the use of herbs is mentioned in Vedic scriptures. In India, it is believed that the taxonomical rank of classification & naming of plants in the Sanskrit language is much older than that of Latin and Greek languages and the study dates back to the Vedic period from 2500 BC to 600 BC [1]. Parts of plants such as fruits, flowers, seed, stem, bark, leaf, stigma, or a root can be classified as herbs nowadays. At first, the 'herb' referred to non-woody plants, as well as those that came from trees and shrubs. The medicinal plants find a varied application in the manufacture of food, flavonoids, medicine, perfumes and are also utilized for sacred activities [2].

Corbichonia decumbens belonging to the family of Lophiocarpaceae is an erect, prostrate-ascending annual or short-lived perennial succulent herb up to 50cm. in height, sometimes with woody root-stock found in the pavements in and around the Annur region of Coimbatore. This potential herb can be well utilized as an effective

source of the drug for various diseases as they have an intrinsic capacity to synthesize aromatic substances such as phenols, and their derivatives [3]. These secondary metabolites tend to exhibit their therapeutic tendencies. These idiosyncratic attributes of plants are the main reason for the researchers to employ them in the drug preparation to reduce the dependency on inorganic compounds. The ethanolic leaf extract of Corbichonia decumbens displayed a good activity in the antimicrobial assay and exhibited a much appreciable zone of inhibition against Aspergillus fumigatus with Ciprofloxacin as standard [4]. The Gas Chromatography-Mass Spectrometry (GCMS) for C. decumbens ethanolic extract revealed the major 30 compounds, which had the bio-potential for becoming an effective drug, this preliminary analysis paved the way for the in-silico works that were carried out in this plant [5].

The disease Allergic Bronchopulmonary Aspergillosis (ABPA) results from IgE-induced pulmonary response to aspergillus species [6]. ABPA can be classified as a severe condition in children, adolescents, and adults with cystic fibrosis (CF) [7]. The Surfactant Protein D (SPD) a lung surfactant protein also called collectins are known to interact with carbohydrate structures on the surfac-

es of a wide range of pathogens, such as viruses, bacteria, and fungi via their carbohydrate recognition domains (CRDs) and enhance phagocytosis and killing by neutrophils and macrophages [8]. SP-D is believed to play a vital role in innate immunity in the lungs by binding through its multiple C- type lectin domains to carbohydrate structures present on a range of viruses, bacteria, yeasts, and fungi [9]. Bio-informatics tools helped in the successful visualization of the target-compound interactions, as drug discovery programs primarily start with the identifications of suitable drug targets, which are biomolecules such as proteins, enzymes, and ion-channels [10]. The initial steps of drug validation can be obtained through insilico and animal models, but the outcome can only be obtained through human clinical trials. The study aims to bring out the efficient use of SP-D with the plant compound of C. decumbens against ABPA disease and to emphasize the significance of C. decumbens as a potential herb as it is one of the first in-silico works in this plant to date.

Materials and Methods

The plant compounds, which were already obtained from GC-MS analysis [5], were retrieved from online databases such as;

PDB, PubChem and Pass Online

The 3D protein structure for the Surfactant Protein- D (SP-D) is recovered from the Protein Data Bank database (PDB ID: 4M18). Dynamic web page region was anticipated utilizing SCFBIO (http://www.scfbio-iitd.res.in/dock/ActiveSite.jsp) online apparatus. The PASS ONLINE predicts 4130 types of biological activities, for which the difference between probabilities will be active (Pa) and probabilities will be inactive (Pi) was calculated. The Pa-Pi values for activities randomly selected from the total list of predicted biological activities will be used as independent regression variables are perused.

Lipinski's rule of 5 helps in distinguishing between drug-like and non-drug-like molecules [11]. It predicts a high probability of success or failure due to drug-likeness for molecules complying with 2 or more of the following rules.

- Molecular mass less than 500 Dalton
- High lipophilicity (expressed as LogP less than 5)
- Less than 5 hydrogen bond donors
- Less than 10 hydrogen bond acceptors
- Molar refractivity must be between 40-130

Molecular Docking Study

MGL tools with AutoGrid4 and AutoDock4 will be used to set up and to perform blind docking calculations between the Ligands and Protein. A crystallized 3-dimensional structure was obtained from the Protein Data Bank (PDB). Receptor (protein) and ligand (complex) files were prepared using Auto Dock Tools. The protein was enclosed in a box with grid points in x, y, and z directions and a grid spacing of 0.375 Å [12]. The center of the grid is set to -6.516, 30.278, and -1.951 Å. Lamarckian genetic algorithms, as implemented in Auto Dock, were employed to perform docking calculations. All other guidelines are default settings. For every individual docking case, the lowest energy docked confirmation, according to the Auto Dock scoring function and several hydrogen bonds was selected as the binding mode. The output from Auto Dock was rendered with PyMol.

PyMol

PyMOL is one of a few open-source visualization tools, which are used, in structural biology. A part of the software's name refers to the fact that it extends, and is extensible by the Python programming language. All the bindings are visualized by using the Structure Visualizing tool pymol viewer, the interaction between the chemical compounds and target protein [13].

Results

The retrieved compounds were analyzed for PASS prediction. Table 1 from which the activity of compounds was confirmed. Further, the compounds were subjected to Absorption, Distribution, Metabolism, and Excretion properties, and the results were tabulated Table 2. The compounds were not found to violate Lipinski's rule of five. First-hand knowledge of this information is much necessary before drug discovery as it has a great impact on the cost, labor, and time duration. Lipinski's rule of five is also called Pfizer's rule of five or the rule of thumb to evaluate drug-likeness to indicate the following properties like molecular weight, octanol/water partition coefficient, hydrogen bond donor, and acceptor. The results of docking studies were recorded in Table 3 and it revealed the compound 1-methyl-3, 5-dinitro-1, 2,4-triazole from Corbichonia decumbens with SP-D shows binding energy of -6.98 Figure 1. The interactions were observed using PyMol.

Table 1: Pass Activity of the selected compounds for docking studies

Compound Name	PubChem ID	Compound Activity (Pass Online)
Quinoline	7047	0.358 0.151 Leukopena
		0.251 0.046 Carcinogenic, group 3
		0,344 0,139 Respiratory failure
		0,266 0,065 Carcinogerus, mouse
		0,283 0,082 Mydratic
		0.231 0.032 Carcinogenic, group 2B
		0,261 0,062 Cercinogenic, rat, male
		0.257 0.069 [Irritation
		The state of the s
		0.341 0.154 Anorexant
		0,212 0,026 Mutagenic, Salmonella
		0,214 0,028 Mutagenic
		0.350 0.164 Brenzhoconstructur
Gentisyl alcohol	188287	0,617 0,049 Euphoria a
Sends y a deciner	100207	0,590 0,024 QT universal prolongamon
		0,620 0,057 Reproductive dysfunction
		0.603 0.041 Arthma 0.616 0.059 Toxic
		0,593 0,036 Respiratory impairment
		0,392 0,036 Embryotoxic
		0,578 0,024 Adresal cortex hypoplassa
		0,603 0,049 Nephrotonia
		0,586 0,088 Tenatogen 0,535 0,010 Fasciculation
		0,599 0.057 Behavioral disturbance
		0.591 0.056 Swesting
1,1-Diethoxy-2methylpropane	519415	0,664 0,005 Eye aritation, weak
, , , , , , , , , , , , , , , , , , , ,		0.685 0.028 Hypercholesterolemic
		0,722 0,069 Shivering
		0.681 0.031 Respiratory fashure
		0,636 0,012 Adrenal cortex hypoplasia
		0,672 0,032 Gustrointestinal hemorrhage
		0,679 0,044 Nauses
		0,673 0,047 Pure red cell aplanus
		0,641 0,024 Hyperunomus
		0.622 0.005 Shan switation, moderate
		0.639 0.025 Hypomagnesemia 0.622 0.008 Skin irritative effect
		M 667 M first Photogram
1	542601	Marri Muso puragenic
1-methyl-3,5-dinitro-1,2,4triazole	542691	0,330 0,190 Sensory disturbance
		0,220 0,001 Carcinogenic, mouse, male
		0.301 0.164 Endocrine discuptor
		0,329 0.186 Respiratory impairment
		0.338 0.206 Hypercholesterolemic
		0.219 0.089 Carcinogenic, mouse
		0.182 0.052 Carcinogenic, group 2B
		0,277 0,147 Weight gain.
		0.307 0.133 (2.1)
		0,307 0,177 Cholestasis
		0,303 0,177 Behavioral disturbance
		0,303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia
2.4 Diabloropygrolo[2.2d]pygimidina	5275052	0.303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telangicetasia -
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telangiectasia 0,263 0,166 Cleft palate
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0.303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telangicetasia -
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telanguectasia 0,263 0,166 Cleft palate 0,230 0,134 Demyelination
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telanguectasia 0,263 0,166 Cleft palate 0,230 0,134 Demyelination 0,316 0,228 Shivering
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telampectasis 0,263 0,166 Cleft palate 0,230 0,134 Demyelination 0,316 0,228 Shivering 0,286 0,206 Palpotation
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telangiectasia 0,263 0,166 Cleft palate 0,230 0,134 Demoyelmation 0,316 0,228 Shivering 0,286 0,206 Palpotation 0,302 0,232 Depression 0,180 0,114 Bullous pemphagoid 0,283 0,224 Respiratory impairment
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral disturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telangiectasia 0,263 0,166 Cleft palate 0,230 0,134 Demyelination 0,316 0,228 Shiveting 0,286 0,206 Palpotation 0,302 0,232 Depression 0,180 0,114 Bullous pemphagoid 0,283 0,224 Respiratory impairment 0,280 0,247 Pseudoporphyvia
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral dinturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telampiectasia
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral disturbance
2,4 Dichloropyrrolo[3,2d]pyrimidine	5375053	0,303 0,177 Behavioral dinturbance 0,211 0,086 Methemoglobinemia 0,171 0,048 Telampiectasia

Table 2: ADME Property of plant compound which were finalized for docking and obeyed the ADMET rules for being a drug molecule.

Molecule	mol_MW (Mo- lecular weight)	accptHB (Acceptor - Hydroge n Bonds)	donorH B (Donor - Hydrogen Bonds)	BBB permeant	GI Absorption	Rule of Five (Lipinski's rule)
Quinoline	146.23	2	0	Yes	High	0
Gentisyl alcohol	173.09	6	0	No	High	0
1,1-Diethoxy-2 methylpropane	129.16	1	0	Yes	High	0
1-methyl-3,5-dini- tro1,2,4-triazole	140.14	3	3	No	High	0
2,4-Dichloropyr-rolo[3,2d]pyrimidine	188.01	2	1	Yes	High	0

Table 3: Interactions of plant compounds with the protein SP-D

Name of ligand	Binding energy	Residues Interacted	Bond length (Å)	No. of bonds formed
Quinoline	-5.25	GLY-237(C-O)	3.5	1
Gentisyl alcohol	-5.06	LEU-233(O-H)	2.3	7
		SER-239(H-O)	2.9	
		(O-N)	2.8	
		GLN-238(H-N)	1.9	
		(O-O)	3.5	
		ALA-264(H-O)	2.2	
		GLY-237(O-N)	3.3	
1,1-Diethoxy-2methylpropane	-3.45	LYS-246(O-N)	3.1	2
		(O-N)	2.7	
1-methyl-3,5-dinitro- 1,2,4-triazole	-6.98	ASN-236(O-N)	3.2	7
		LYS-246(O-N)	2.8	
		GLU-232(O-O)	2.8	
		(N-O)	3.0	
		(O-O)	3.1	
		PHE-234(O-O)	2.9	
		GLN-236(O-N)	2.9	
2,4- Dichloropyrrolo[3,2d]pyrimidine	-5.17	GLU-232(H-O)	2.1	1

PYMOL INTERACTIONS




Fig 1 1-methyl-3, 5-dinitro-1, 2, 4-triazole Vs SP-D This compound displayed excellent binding energy of -6.98.




Fig 2 Quinoline Vs SP-D Binding energy of this compound- 5.25




Fig 3 2,4-Dichloropyrrolo[3,2-d]pyrimidine Vs SP-D Binding Energy of this compound- 5.17

Discussion

The disease Allergic Bronchopulmonary Aspergillosis (ABPA), caused by the fungi Aspergillus fumigatus is a hypersensitivity lung disease that is rarely found in 10% of persons having cystic fibrosis [14]. A positive response to this disease was created using the in-silico tools, which succored in the successful docking analysis. The ABPA is more ubiquitous in patients who have been diagnosed with asthma [15]. The compounds displayed acceptable binding energy with surfactant protein D, as these are lung surfactant-related hydrophilic proteins that have been implicated in surfactant homeostasis and pulmonary innate immunity [16]. It is believed that synthesis and secretion of this collectin increase with acute injury and epithelial activation [17]. The binding of SP-D with this phyto-compound will surely aid in the development of a more activated protein target, which in turn can produce striking results thereby providing an insight into the development and modification of a target in the fungal disease caused by A. fumigatus. The docking studies of 1-methyl-3, 5-dinitro-1, 2, 4-triazole with SP-D revealed 5 active sites, a similar result was also shown in the transport of GLUT-1 [18]. As to get a conclusive result the same receptor was docked with five different ligands to bring out the variance. Similar work was carried to evaluate the ability of each docking protocol to identify the binding of the same receptor with two different ligands [19].

Conclusion

The chemical compound 1-methyl-3,5-dinitro-1,2,4-triazole had a much significant binding energy of -6.98 and interactions with active site residue ASN-236, LYS-246, GLU-232, PHE-234 and,

GLN-236. A wide variety of compounds were selected for this study but after scrutinizing only handful of standard compounds were considered. The above plant compounds could be explored more for ABPA & the identification of an efficient and potential drug molecule by enhancing the activity of SP-D protein and thus making it a super protein by combining this compound.

Declarations Availability of Data Material

The preprint of the article is available at Research Square. The DOI is https://doi.org/10.21203/rs.3.rs-463617/v1

Author Contributions

A. Arunprasath- Conceptualization, supervision, and review. Sreeram. S- Methodology, data extraction, writing- original draft preparation. V Sankara Vel- Data Analysis

References

- Balkrishna, Acharya, et al. "Ancient Indian rishi's (Sages) knowledge of botany and medicinal plants since Vedic period was much older than the period of Theophrastus, A case study-who was the actual father of botany?." International Journal of Unani and Integrative Medicine 3.3 (2019): 40-44.
- Introduction and Importance of Medicinal Plants and Herbs | National Health Portal of India (2016) https://www.nhp.gov.in/ introduction-and-importance-of-medicinal-plants-and-herbs_mtl
- 3. Geissman, T. A. "Flavoniod compounds, tannins, lignins and related compounds." Pigments, Isoprenoid Compounds and

- Phenolic Plant Constituents 9 (1963): 265.
- Vidyacharani, d., & Arunprasath, a. (2020) Evaluations of secondary metabolites antioxidant and antimicrobial potential in leaf extracts of Corbichonia decumbens (FORSSK.) EX-ELL. Asian J Pharm Clin Res, 13(11), 181-183. https://doi. org/10.22159/ajpcr.2020.v13i11.39004
- Saranya, M. S., and A. Arunprasath. "Evaluation of phytochemical compounds in Corbichonia decumbens (Frossk).
 Excell by using Gas Chromatography–Mass Spectrometry."
 Journal of Applied and Advanced Research 4.3 (2019): 89-93.
- Kanu, Adaobi, and Kalpana Patel. "Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab)." Pediatric pulmonology 43.12 (2008): 1249-1251.
- de Almeida, Marina Buarque, Maria Helena F. Bussamra, and Joaquim Carlos Rodrigues. "Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients." Paediatric respiratory reviews 7.1 (2006): 67-72.
- 8. Wright, Jo Rae. "Immunoregulatory functions of surfactant proteins." Nature Reviews Immunology 5.1 (2005): 58-68.
- Reid, Kenneth BM. "Interactions of surfactant protein D with pathogens, allergens and phagocytes." Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1408.2-3 (1998): 290-295.
- 10. Terstappen, Georg C., and Angelo Reggiani. "In silico research in drug discovery." Trends in pharmacological sciences 22.1 (2001): 23-26.
- 11. Chen, Xiaoxia, et al. "Analysis of the physicochemical properties of acaricides based on Lipinski's rule of five." Journal of computational biology 27.9 (2020): 1397-1406.

- 12. Holt, Patrick A., Jonathan B. Chaires, and John O. Trent. "Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex." Journal of chemical information and modeling 48.8 (2008): 1602-1615.
- DeLano, W.L. (2002) PyMOL. http://virology.wisc.edu/acp/ Classes/DropFolders/Drop660_lectures/2013_660/L01_Py-MOL 2013r.pdf
- Keown, Karen, et al. "An investigation into biomarkers for the diagnosis of ABPA and aspergillus disease in cystic fibrosis." Pediatric Pulmonology 54.11 (2019): 1787-1793.
- 15. Geller, David E., et al. "Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics." Chest 116.3 (1999): 639-646.
- 16. Kishore, Uday, et al. "Protective roles of pulmonary surfactant proteins, SP-A and SP-D, against lung allergy and infection caused by Aspergillus fumigatus." Immunobiology 205.4-5 (2002): 610-618.
- 17. Piboonpocanun, Surapon, et al. "Surfactant protein A binds Mycoplasma pneumoniae with high affinity and attenuates its growth by recognition of disaturated phosphatidylglycerols." Journal of Biological Chemistry 280.1 (2005): 9-17.
- 18. Cunningham, Philip, Iram Afzal-Ahmed, and Richard J. Naftalin. "Docking studies show that D-glucose and quercetin slide through the transporter GLUT1." Journal of Biological Chemistry 281.9 (2006): 5797-5803.
- 19. Ricci, C. G., & Netz, P. A. (2009). Docking studies on DNA-ligand interactions: building and application of a protocol to identify the binding mode. J. Chem. Inf. Model., 49(8), 1925-1935.

Copyright: ©2022 A. Arunprasath. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.